Monalizumab, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, CETUXIMAB
D7310C00001
Phase 3 small_molecule active
Quick answer
Monalizumab, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, CETUXIMAB for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active